Q-omics provides the consensus-scored TRIM49C profile across patient tissues and cancer cell-line models. TRIM49C expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRIM49C is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, TRIM49C RNA expression shows 10,026 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, THCA, and COAD as cancer lineages where TRIM49C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM49C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM49C survival associations across molecular data types. TRIM49C RNA expression shows survival associations in the most cancer types (12), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM49C RNA expression–survival associations across cancer types. High TRIM49C expression shows unfavorable associations in BLCA, UCEC, HNSC, LUAD and CHOL, but favorable associations in LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRIM49C RNA expression.
This table summarizes TRIM49C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM49C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM49C shows lower tumor expression in THCA and higher tumor expression in LUAD and LUSC. The THCA box plot shows higher TRIM49C RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .041).
This table shows molecular features associated with TRIM49C in patient tissues and cancer cell lines. In patient samples, TRIM49C shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM49C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
